Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Enhanced nucleic acid therapeutics: synthetic sequence elements for boosting protein expression in genetic medicines

Award Number: R44TR006096
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/08/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

Enhanced nucleic acid therapeutics: synthetic sequence elements for boosting protein expression in genetic medicines - Nucleic acid-based medicines have demonstrated remarkable potential in preventing and treating a wide range of diseases, as exemplified by their crucial role in the COVID-19 pandemic response. However, several challenges remain, including inherent instability, manufacturing complexities, and the need for efficient delivery mechanisms. The development of new nucleic acidbased medicines offers potential solutions to these issues by reducing dosage requirements, lowering manufacturing costs, and improving efficacy. Noncoding sequence elements such as 5' untranslated regions and internal ribosome entry sites required for protein expression from these medicines offer promising targets to improve efficacy, lower manufacturing costs, and pave the way for the next generation of genetic medicines. In collaboration with an established mRNA medicines company, Primrose Bio has created a novel ultra-high-throughput platform for non-coding sequence element discovery and evolution. This platform has higher throughput and flexibility than other non-coding sequence discovery systems described to date and has unlimited potential to discover highly efficient synthetic non-coding sequence elements that stimulate protein expression. In this project, Primrose Bio will utilize this platform to create a panel of optimized synthetic 5' noncoding sequence elements for enhancing protein expression that can be seamlessly integrated into nucleic acid therapeutics. These sequences elements will be tested in partnership with SoCal Biosciences. The sequence elements developed in this program will find direct commercial outlets through existing and new partners developing disruptive therapies, such as cancer therapeutics.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $951,630 )
2026	2026	PRIMROSE BIO, INC.	10790 ROSELLE ST	SAN DIEGO	CA	92121	SAN DIEGO	USA	National Center for Advancing Translational Sciences	000	1	7/8/2026	NEW	$951,630
														Subtotal = $951,630

Grand Total All Awards = $951,630

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Enhanced nucleic acid therapeutics: synthetic sequence elements for boosting protein expression in genetic medicines

Award Number: R44TR006096

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/08/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer